Name
Celea Therapeutics
What We Do
Celea Therapeutics is dedicated to advancing transformative treatments for people with serious respiratory diseases. Drawn from the Latin word for "sky," our name reflects our mission: to rise above the status quo and deliver therapies that change lives.
Our lead program, deupirfenidone (LYT-100), is in Phase 3 development with the potential to set a new standard of care for idiopathic pulmonary fibrosis (IPF) and other fibrotic lung diseases.
Celea was founded by PureTech Health plc (LSE: PRTC), a biotherapeutics company dedicated to giving life to science.
Our lead program, deupirfenidone (LYT-100), is in Phase 3 development with the potential to set a new standard of care for idiopathic pulmonary fibrosis (IPF) and other fibrotic lung diseases.
Celea was founded by PureTech Health plc (LSE: PRTC), a biotherapeutics company dedicated to giving life to science.
Website
Categories
Pharmaceutical
Address
6 Tide Street
Ste 400
Boston, MA 02210
United States
Ste 400
Boston, MA 02210
United States